Osel, Inc.

BALTIMORE, MD 21205

SBIR Award Summary

Total Number of Awards 12
Total Value of Awards $5.23MM
First Award Date 09/01/99
Most Recent Award Date 08/01/15

Key Personnel

Last Name Name Awards Contact
Chang Chia-Hwa Chang 2
Simpson David A Simpson 1
Rozinov Michael Rozinov 1
Martin Patrick K Martin 2
Lagenaur Laurel A Lagenaur 5
Parks Thomas P Parks 1
JONES-SMITH JESSICA JONES-SMITH 0
DOHENY KIMBERLY DOHENY 0

12 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 08/01/15 - 07/31/16

DESCRIPTION: Women bear the brunt of the global AIDS epidemic due in part to their inherent social and biological vulnerability. Biologically, the cervical and vaginal mucosae are vulnerable targets for HIV transmission. In healthy women of childbearing age, mucosal antibodies and microbiota, including Lactobacillus jensenii, help protect these ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 08/07/14 - 07/31/15

DESCRIPTION: Women bear the brunt of the global AIDS epidemic due in part to their inherent social and biological vulnerability. Biologically, the cervical and vaginal mucosae are vulnerable targets for HIV transmission. In healthy women of childbearing age, mucosal antibodies and microbiota, including Lactobacillus jensenii, help protect these ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 04/01/12 - 03/31/13

DESCRIPTION (provided by applicant): Women bear the brunt of the global AIDS epidemic due in part to their inherent social and biological vulnerability. Biologically, the cervical and vaginal mucosae are vulnerable targets for HIV transmission. In healthy women of childbearing age, mucosal antibodies and microflora, including Lactobacillus jense...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-OD-09-009
Budget: 08/01/10 - 07/31/11

DESCRIPTION (provided by applicant): This application focuses on the development of a novel bacterial therapeutics targeting bacterial vaginosis (BV)-associated biofilm for the prevention and treatment of recurrent BV using a novel strain of Lactobacillus jensenii with a disrupted pox1 gene in the chromosome that exhibits highly potent activity ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/22/05 - 08/31/06

DESCRIPTION (provided by applicant): Clostridium difficile is the cause of pseudomembranous colitis and the leading cause of nosocomial intestinal infections in the U.S. It is responsible for substantial morbidity and has a significant economic impact on the health care system. C. difficile-associated disease (CDAD) is caused by antibiotics and...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/03 - 08/31/03

DESCRIPTION (provided by applicant): Genital herpes infection is extremely common throughout the world and continues to increase in incidence, Genital herpes is caused by the sexual transmission of herpes simplex virus type 2 (HSV-2), although a smaller, but increasing, percentage of cases are caused by herpes simplex virus type 1 (HSV-1) Genita...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/03 - 02/29/04

DESCRIPTION: (Provided by Applicant) The predominant mode of HIV transmission worldwide is via heterosexual contact, with the cervicovaginal mucosa serving as the main site of viral entry in women. Realizing that the vaginal mucosa is colonized with large numbers of non-pathogenic lactobacilli, we propose an innovat...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/02 - 03/14/03

DESCRIPTION: (Provided by Applicant) Osel was founded to develop and commercialize a novel approach to prevent vaginal HIV transmission. We propose to colonize the vaginal mucosa with non-pathogenic lactobacilli, genetically modified to bind and inactivate HIV. We are constructing recombinant lactobacilli that express the potent HIV-inhibitor, c...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/02 - 12/31/02

DESCRIPTION (provided by applicant): Osel Inc. is striving to develop a novel approach to prevent vaginal HIV transmission. This approach involves genetically modifying non-pathogenic bacteria, resembling those found on mucosal surfaces, to produce molecules that have the capacity to bind, trap, and inactivate HIV. By colonizing the vaginal ca...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/02 - 02/28/03

DESCRIPTION: (Provided by Applicant) The predominant mode of HIV transmission worldwide is via heterosexual contact, with the cervicovaginal mucosa serving as the main site of viral entry in women. Realizing that the vaginal mucosa is colonized with large numbers of non-pathogenic lactobacilli, we propose an innovat...

Load More